The Sloane Project, a UK‐wide prospective audit of screen‐detected DCIS (http://www.sloaneproject.co.uk), and LORIS, a UK phase III trial comparing surgery with active monitoring for low‐risk DCIS, will be useful for evaluating the clinical value of SOX11 expression and its correlation with DCIS progressing to invasive breast cancer 42. This evidence concerns the gene SOX11 and ductal breast carcinoma in situ.